Key Stats for Illumina Stock
- Past-Week Performance: -7.3%
- 52-Week Range: $68.7 to $155.5
- Current Price: $124.3
What Happened?
Illumina, the dominant maker of DNA sequencing instruments used in cancer diagnostics and genetic research, delivered 20% clinical consumables growth outside China in Q4 and now trades at $124.28, more than 80% above its 52-week low of $68.70, as a product cycle inflection finally shows up in the numbers.
Last February 5, Illumina reported Q4 adjusted EPS of $1.35 against a $1.23 estimate while beating revenue estimates, then on February 24 launched TruPath Genome, a whole-genome sequencing workflow priced at $395 per genome that eliminates traditional library preparation and runs on the company’s 890-unit NovaSeq X installed base immediately.
The NovaSeq X, Illumina’s flagship high-throughput sequencer that processes billions of DNA reads per run, placed over 100 units in Q4 — the second highest quarterly total since its 2023 launch — while total sequencing output on connected instruments grew more than 30% YoY, outpacing any comparable throughput metric Roche has publicly disclosed for its competing AXELIOS 1 platform.
On February 23, Illumina unveiled an 18-month NovaSeq X roadmap targeting Q70 quality scores and a 40% output increase to 35 billion reads, directly enabling high-sensitivity minimal residual disease testing, a fast-growing cancer monitoring application that no current platform supports at that quality threshold.
CEO Jacob Thaysen stated at the TD Cowen Health Care Conference on March 3 that “Illumina will be able to grow very strongly going forward, at least high single-digit growth even in a very competitive space,” directly connecting that commitment to TruPath’s multiplexing roadmap, the SomaLogic proteomics acquisition closed January 30, and $643 million remaining in share repurchase authorization.
Wall Street’s Take on ILMN Stock
The TruPath Genome launch on February 24, which eliminates library preparation and runs immediately on all 890 NovaSeq X instruments, directly accelerates the clinical consumables volume growth that drives Illumina’s margin recovery thesis.
EBITDA margin, the measure of operating profitability before interest and taxes that tracks how efficiently Illumina converts sequencing volume into cash, recovered from a 10.8% trough in FY2023 to 27.8% in FY2025 and is projected to reach 29.5% in FY2026 as clinical volumes compound.
Alongside margin expansion, normalized EPS recovered from a $0.86 trough in FY2023 to $4.84 in FY2025 and is projected to reach $5.84 in FY2027, a 13.9% YoY jump that reflects the operating leverage building as the NovaSeq X installed base drives recurring consumables revenue.
Wall Street remains cautiously positioned despite the recovery: 8 buys and 1 outperform against 8 holds and 3 sells/underperforms, with a mean price target of $136.05 implying 9.5% upside from the March 9 close of $124.28, suggesting analysts have not yet fully priced in the clinical consumables inflection.
The target range spans $80.00 on the low end to $170.00 on the high end, with the floor tied to a scenario where NIH funding deterioration or Roche AXELIOS 1 competition disrupts research instrument placements, and the ceiling contingent on clinical consumables sustaining mid-teens growth through 2027.
What Does the Valuation Model Say?
TIKR’s mid-case model prices ILMN at $195.12 by December 2030, implying 57% total return at a 9.8% annualized IRR, driven by mid-case revenue CAGR of 5.5% and net income margin expanding from 17.5% in FY2026 to 22.3% by FY2030.
The model requires only 5.5% revenue CAGR to reach $195, yet clinical consumables alone grew 20% ex-China in Q4, making the model’s core assumption appear conservative against current run rates.
Over 30 early-access customers piloted TruPath before its February 24 launch, and Broad Clinical Labs adopted it immediately, confirming real clinical demand rather than speculative pipeline interest behind the margin expansion thesis.
CEO Jacob Thaysen committed at the March 3 TD Cowen conference to “at least high single-digit growth” even in a highly competitive market, directly anchoring the model’s 5.5% mid-case CAGR as a floor, not a ceiling.
If NIH funding disruptions deepen and research consumables decline faster than the mid-to-high single-digit assumption embedded in guidance, the revenue CAGR compresses and the $195 target price moves materially lower.
Q1 2026 results are the first hard check: watch whether clinical consumables sustain double-digit to mid-teens growth and whether the $1.02 to $1.07 EPS guidance holds, confirming that the NovaSeq X flywheel continues post-TruPath launch.
Should You Invest in Illumina, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ILMN stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Illumina, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ILMN stock on TIKR for Free →
